A redesigned radioactive peptide meant to spare the kidneys of neuroendocrine tumor patients ended up parking its radiation somewhere else instead. In a first-in-human trial of six patients, the bone marrow, not the kidney, was the organ that set the ceiling on how much drug the doctors could safely give.
The drug is 177Lu-DOTA-EB-TATE, and the finding was published September 24 in the Journal of Nuclear Medicine ↗. It is a variant of the approved therapy Lutathera (177Lu-DOTATATE), a peptide that carries a radioactive lutetium atom to tumors. The peptide half is a close cousin of octreotide, a somatostatin analog that latches onto a receptor called SSTR2 that neuroendocrine tumors carry in abundance. Dock the peptide, and the attached radiation irradiates the tumor from inches away.
Lutathera's known weakness is that it washes out of the bloodstream fast, so a lot of each dose leaves the body before it reaches the tumor, and what passes through the kidneys on the way out can damage them. The redesign bolts on a molecule called Evans blue that grabs onto albumin, the most abundant protein in blood. Tethered to albumin, the peptide circulates far longer, giving it more chances to find and stick to a tumor. More dwell time, more delivered dose. That was the pitch, and an earlier trial of a related albumin-binding radioligand had already shown the lingering-longer strategy could lift tumor response.
Here is what six patients showed instead. The team, using a standard 3-plus-3 escalation, gave nominal activities of 1.85, 3.70, or 5.55 gigabecquerels across two cycles six weeks apart, in adults with inoperable gastroenteropancreatic neuroendocrine tumors. The kidneys came through fine. The median kidney dose was 4.8 gray per cycle (a gray is the unit of absorbed radiation), and with dosimetry tailored to each patient after the first cycle, no kidney toxicity showed up. But at the 3.70 gigabecquerel level, one patient developed persistent grade 3 febrile neutropenia, a dangerous drop in infection-fighting white cells, and an outside cohort confirmed the pattern. The same lingering that was supposed to help had kept the radiation circulating long enough to suppress the marrow.
So the trial set the maximum tolerated activity at 3.70 gigabecquerels and recommended the lowest tested dose, 1.85 gigabecquerels per cycle, for future studies, specifically to avoid irreversible marrow damage. Read plainly, the redesign traded one dose-limiting organ for another. The conclusion notes the drug actually delivered higher radiation doses to the kidney than standard Lutathera does, and the kidneys tolerated it, but the marrow would not let them push the dose up.
The efficacy signal was modest and is not the point of a six-person safety study. Five of six patients had stable disease at three months and one had a partial response, but two had progressed by six months after treatment. What the trial actually establishes is a dosing envelope: because each unit of this drug packs more punch and stays longer, you give far less of it. Lutathera's standard course is 7.4 gigabecquerels four times over, roughly 30 gigabecquerels total. The recommended EB-TATE schedule is 1.85 gigabecquerels twice, about an eighth of that, delivered in a shorter two-cycle regimen the authors argue lets doctors read out response sooner.
The caveats are the size of the study. Six patients cannot tell you how often the marrow toxicity happens, whether the two-cycle schedule holds up against Lutathera's four, or which patients should get which. Dose-limiting toxicity is a finding about safety limits, not a win. The value here is negative knowledge delivered early: an albumin-binding trick that reads as a clean upgrade on paper carries a specific, quantified cost, and the trial found the ceiling before a larger study could overshoot it.
The receptor these drugs aim at, SSTR2 ↗, is the same target behind the somatostatin analog octreotide ↗ and the whole radioligand class built on that scaffold. Peptidemodel has covered the lingering-longer strategy from the optimistic side before, when making a radioactive peptide linger lifted response in a small trial ↗. This piece is the other edge of the same knife: linger too long, and the marrow sends the bill.